News
AWHL
0.430
-4.44%
-0.020
Weekly Report: what happened at AWHL last week (0525-0529)?
Weekly Report · 5d ago
Aspira Women’s Health, Cleveland Clinic Launch Diagnostics Collaboration
TipRanks · 05/26 13:34
Weekly Report: what happened at AWHL last week (0518-0522)?
Weekly Report · 05/25 10:12
Weekly Report: what happened at AWHL last week (0511-0515)?
Weekly Report · 05/18 10:12
Aspira Women’s Health turns to Q1 FY26 profit; revenue falls 14% to 2 million
PUBT · 05/15 20:04
Aspira: Q1 Earnings Snapshot
Barchart · 05/15 15:21
Weekly Report: what happened at AWHL last week (0504-0508)?
Weekly Report · 05/11 10:09
Weekly Report: what happened at AWHL last week (0427-0501)?
Weekly Report · 05/04 10:07
Aspira Women’s Health Appoints John Strahley as CFO
TipRanks · 04/30 22:31
Aspira Women's Health names John Strahley CFO, chief accounting officer
PUBT · 04/30 21:43
Weekly Report: what happened at AWHL last week (0420-0424)?
Weekly Report · 04/27 10:10
Aspira Women’s Health announces annual shareholder meeting
PUBT · 04/24 11:19
Aspira Women’s Health expands molecular lab to advance ENDOinform endometriosis blood test
PUBT · 04/23 12:55
Weekly Report: what happened at AWHL last week (0413-0417)?
Weekly Report · 04/20 10:06
Weekly Report: what happened at AWHL last week (0406-0410)?
Weekly Report · 04/13 10:09
Weekly Report: what happened at AWHL last week (0330-0403)?
Weekly Report · 04/06 10:10
Aspira operating loss narrows 51% to $7.9 million in FY25
Reuters · 04/01 19:47
Aspira Women’s Health Delays Annual 10-K Filing
TipRanks · 04/01 15:28
Aspira: Q4 Earnings Snapshot
Barchart · 04/01 15:15
Aspira Women’s Health delays annual 10-K filing, cites tax provision accounting work
Reuters · 04/01 11:19
More
Webull provides a variety of real-time AWHL stock news. You can receive the latest news about Aspira Womens Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About AWHL
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.